Veru: Safer Bet Is To Wait For The AdComm Verdict (NASDAQ:VERU)
seekingalpha.com
news
2022-10-17 18:17:00

TexPhoto/E+ via Getty Images Investment Overview I gave Miami, Florida based biotech Veru Inc. (NASDAQ:VERU) a bullish rating in my last post on the company back in July based on a number of factors, but the main one was the biotech's opportunity to win Emergency Use Authorization ("EUA") for lead asset Sabizabulin to treat hospitalized COVID patients. Given the unmet need, this could potentially translate to a blockbuster (>$1bn per annum) revenue opportunity. Sabizabulin is "an oral agent that
